Catalog # 10-3743

Tafamidis

CAS# 594839-88-0

PF-06291826

2-(3,5-Dichlorophenyl)-6-benzoxazolecarboxylic acid

Lot # X102240



A potent and selective transthyretin (TTR) kinetic stabilizer. It binds selectively and with negative cooperativity to the two normally unoccupied thyroxine binding sites of the TTR tetramer (K_d = ~2 and ~200 nM)[1]. Stabilizes wild-type and mutant TTR under varying conditions *in vitro* (EC_{50}=2.7-3.2 μM).[1] Clinically useful for the treatment of familial amyloid polyneuropathy[2,3] and TTR-related cardiomyopathy[4].

1) Bulawa *et al*. (2012), *Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits amyloid cascade*; Proc. Natl. Acad. Sci. USA, **109** 9629

2) Scott (2014), *Tafamidis: a review of its use in familial amyloid polyneuropathy*; Drugs, **74** 1371

3) Zhao *et al*. (2019), *Tafamidis, a Noninvasive Therapy for Delaying Transthyretin Familial Amyloid Polyneuropathy: Systemic Review and Meta-analysis*; J. Clin. Neurol., **15** 108

4) Lorenzini and Elliott (2019), *Tafamidis for the treatment of transthyretin amyloidosis*; Future Cardiol., **15** 53

PHYSICAL DATA

Molecular Weight:	308.12
Molecular Formula:	$C_{14}H_7Cl_2NO_3$
Purity:	98% by TLC
	NMR: (Conforms)
Solubility:	DMSO (up to 20 mg/ml)
Physical Description:	Off-white solid
Storage and Stability:	Store as supplied desiccated at -20°C for up to 2 years from the date of purchase. Solutions in DMSO may be stored at -20°C for up to 3 months.

Focus Biomolecules LLC 400 Davis Drive, Suite 600 Plymouth Meeting PA 19462

www.focusbiomolecules.com